Medicines In The Environment: EU Moots Action On ‘Green’ Manufacturing, Pack Sizes, Discharges
Executive Summary
Stakeholders in the EU are being asked to give their views on ways of addressing the problem of pharmaceuticals posing public health risks when they enter the environment via their manufacture, use and disposal. “Green” manufacturing and design, closer monitoring of discharges and more appropriate pack sizes are among proposals put forward.
You may also be interested in...
EU Calls For Action To Reduce Environmental Impact Of Pharmaceuticals
The European Commission has outlined actions that the pharmaceutical industry and other stakeholders need to take in order to minimize the risk of pharmaceuticals contaminating the environment.
Drug Industry Raises ‘Green’ Concerns Over Forthcoming EU Environment Strategy
The European Commission’s strategy on Pharmaceuticals in the Environment is expected to be published by the summer. The pharmaceutical industry has concerns about what it is likely to include.
Industry Outlines Concerns Over EU Proposals On Pharmaceuticals In The Environment
EFPIA has generally welcomed the European Commission’s consultation on pharmaceuticals in the environment, but says it also has concerns over certain aspects of the proposals that it thinks are impracticable and could delay patient access to medicines.